This issue has reports from the recent 2nd European HIV Drug Resistance Workshop and 5th International Workshop on Clinical Pharmacology of HIV Therapy conferences plus two final Retrovirus reports. One of the most import presentations from the PK meeting was the analysis of tipranavir interactions with other protease inhibitors (see page 3).
In this issues Treatment Access, Graham McKerrow provides a round up of recent developments in pricing agreements and access issues in resource poor countries.
We are hardly the first to point this out, but we could never have imagined five years ago, that effective fixed dose combinations would become available at less than 3% ot the original cost of HAART and that agreement for global funding would be approved approved for many programmes.
However, even when funding has been approved, or new lower price deals announced, the reality is that very few HIV-positive people have so far actually received antiretrovirals.
Whether even 300,000 people will be on-treatment by 2005 is still in doubt, and we’re almost halfway through 2004.
HIV Treatment Bulletin
HTB is a monthly journal published in print and electronic format by HIV i-Base. As with all i-Base publications, subscriptions are free and can be ordered directly from the i-Base website:
by sending an email to:
or by fax or post using the form on the back page.
Editor in Chief: Paul Blanchard
Editor: Simon Collins
Associate Editor: Graham McKerrow
Commissioning Editor: Polly Clayden
Medical Consultants:
Dr Sanjay Bhagani, Royal Free Hospital, London.
Dr Karen Beckerman, Bellevue Hospital, New York.
Dr Gareth Hardy, Royal Free Hospital, London.
Dr Saye Khoo, University of Liverpool Hospital.
Prof. Clive Loveday, International Laboratory Virology Centre.
Dr Graeme Moyle, Chelsea & Westminster Hosp, London.
Dr Stefan Mauss, Düsseldorf.
Dr Stephen Taylor, Birmingham Heartlands Hospital.
Dr Gareth Tudor-Williams, Imperial College, London.
HTB is a not-for-profit community publication that aims to provide a review of the most important medical advances related to clinical management of HIV and its related conditions as well as access to treatments. Comments to articles are compiled from consultant, author and editorial responses.
Some articles are reproduced from other respected sources and copyright for these articles remains with the original authors and sources, as indicated at the end of each article.
We thank those organisations for recognising the importance of providing widely distributed free access to information both to people living with HIV and to the healthcare professionals involved in their care. We also thank them for permission to distribute their excellent work and we encourage HTB readers to visit the source websites for further access to their coverage of HIV treatment.
Articles written and credited to i-Base writers, as with all i-Base originated material, remains the copyright of HIV i-Base, but these articles may be reproduced by community and not-for-profit organisations without individual written permission and reproduction is encouraged. A credit and link to the original author, the HTB issue and the i-Base website is always appreciated.
HIV i-Base receives unconditional educational grants from Charitable Trusts, individual donors and pharmaceutical companies.All editorial policies are strictly independent of funding sources.
HIV i-Base
Third Floor East, Thrale House
44-46 Southwark Street, London SE1 1UN
T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
HIV i-Base is a registered charity no 1081905 and company reg no 3962064.
HTB is also known as DrFax
 |
 |
 |
 |